Trial Profile
A Phase IIb, Randomized, Double-blinded, Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2017
Price :
$35
*
At a glance
- Drugs Autologous adipose-derived mesenchymal stem cell therapy-AbelZeta Pharma (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Cellular Biomedicine Group
- 09 Feb 2017 Status changed from recruiting to completed.
- 12 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016.
- 13 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2016.